- Budenheim becomes the first co-brand partner to join Brenntag’s BYPHAR brand globally
- The partnership underscores Brenntag’s ambition to make BYPHAR a leading ecosystem of high quality, GMP compliant solutions for the biopharmaceutical industry.
Brenntag, the global market leader in chemicals and ingredients distribution, today announced a strategic partnership with Budenheim, a leading manufacturer of high-purity phosphate specialties, on biopharma phosphate solutions through complementary commercial models.
The partnership combines Budenheim’ s expertise in manufacturing high-quality phosphate products with Brenntag's biopharma services and distribution capabilities to better serve customers requiring both commercial-scale supply and smaller biopharma-oriented pack sizes. The collaboration supports the increasing demand for high-purity phosphate products used in applications such as buffer preparation, cell culture, downstream processing and formulation, while expanding access to flexible packaging formats for the growing biopharmaceutical market.
Under the collaboration, Budenheim’ s dedicated biopharma phosphates portfolio will be available through BYPHAR, Brenntag's Biopharma brand. Brenntag will offer these first co-branded high purity phosphates in pack sizes of 15 kg or less, available globally and providing greater flexibility from early development through commercial manufacturing. Budenheim’ s own brand PharSQ Pure, available in packaging of 25 kg and above, will be distributed by Brenntag solely across Europe.
The portfolio comprises 7 GMP-manufactured phosphates designed for biopharmaceutical applications: Monosodium Phosphate Anhydrous / Monohydrate / Dihydrate as well as Disodium Phosphate Anhydrous / Dihydrate / Heptahydrate and Dodecahydrate. These products are monograph compliant, microbiologically controlled, endotoxin tested and supplied in biopharma-oriented packaging to meet the quality requirements of biopharmaceutical manufacturing.
"This partnership brings together complementary strengths to provide customers with greater flexibility and improved access to high-quality phosphate solutions for biopharmaceutical applications," said Gearoid O'Rourke, Senior Director BioPharma at Brenntag Pharma.
“Our long-standing partnership with Brenntag creates value for biopharma customers across Europe. Brenntag’s strong distribution reach supports our PharSQ Pure in larger packaging, while its own BYPHAR brand makes it available in smaller, more flexible formats as well”, said Jorge Flores Martin, Senior Vice President Marketing & Sales Division Life Science, Budenheim.
About Budenheim:
Budenheim is a globally operating specialty chemical company and a leading manufacturer of phosphate specialties for pharmaceutical and biopharmaceutical applications, recognized for its high-quality standards, manufacturing expertise and long-standing market presence. With its innovative portfolio, the chemical specialist provides sustainable products, services, and application concepts for various markets. With sites in Germany, Spain, the Netherlands, the USA, Mexico, China, Singapore, and India, Budenheim generates annual revenue of several hundred million euros and employs more than 1,350 people. For more information about Budenheim, visit: https://budenheim.com
Budenheim is a globally operating specialty chemical company and a leading manufacturer of phosphate specialties for pharmaceutical and biopharmaceutical applications, recognized for its high-quality standards, manufacturing expertise and long-standing market presence. With its innovative portfolio, the chemical specialist provides sustainable products, services, and application concepts for various markets. With sites in Germany, Spain, the Netherlands, the USA, Mexico, China, Singapore, and India, Budenheim generates annual revenue of several hundred million euros and employs more than 1,350 people. For more information about Budenheim, visit: https://budenheim.com
